1. Extremely Thermostabilizing Core Mutations in Coiled-coil Mimetic Proteins of HIV-1 gp41 Produce Diverse Effects on Target Binding but Do Not Affect Their Inhibitory Activity. Cano-Muñoz, M., S. Cesaro, B. Morel, J. Lucas, C. Moog, and F. Conejero-Lara. Biomolecules, 2021. 11(4): 566. PMID[33921495]. PMCID[PMC8069472].
[PubMed]. HIV_04_2021.
2. Phage Display-directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication. Desimmie, B.A., M. Humbert, E. Lescrinier, J. Hendrix, S. Vets, R. Gijsbers, R.M. Ruprecht, U. Dietrich, Z. Debyser, and F. Christ. Molecular Therapy, 2012. 20(11): p. 2064-2075. PMID[22828501]. PMCID[PMC3498793].
[PubMed]. HIV_04_2021.
3. 3,4-Dihydro-2H-1,3-benzoxazines and Their Oxo-derivatives - Chemistry and Bioactivities. El-Din, N.A.E. Journal of the Serbian Chemical Society, 2021. 86(3): p. 213-246. ISI[000632891900001].
[WOS]. HIV_04_2021.
4. Flavonoids and Acid-hydrolysis Derivatives of Neo-Clerodane diterpenes from Teucrium flavum Subsp. Glaucum as Inhibitors of the HIV-1 Reverse Transcriptase-associated RNase H Function. Fois, B., A. Corona, E. Tramontano, S. Distinto, E. Maccioni, R. Meleddu, P. Caboni, C. Floris, and F. Cottiglia. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021. 36(1): p. 749-757. PMID[33715562]. PMCID[PMC7952052].
[PubMed]. HIV_04_2021.
5. Synthesis, Antimicrobial Activity, anti-HIV Activity, and Molecular Docking of Novel 5-, 6- and 7-Membered Ring (1H-Pyrrol-2-yl)aminolactams. Jassem, A.M. and A.M. Dhumad. ChemistrySelect, 2021. 6(10): p. 2641-2647. ISI[000627830300019].
[WOS]. HIV_04_2021.
6. 2,4,5-Trisubstituted pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. Kang, D., F.X. Ruiz, Y. Sun, D. Feng, L. Jing, Z. Wang, T. Zhang, S. Gao, L. Sun, E. De Clercq, C. Pannecouque, E. Arnold, P. Zhan, and X. Liu. Journal of Medicinal Chemistry, 2021. 64(7): p. 4239-4256. PMID[33734714].
[PubMed]. HIV_04_2021.
7. Anandenanthera colubrina (Vell.) Brenan as an Inhibitor of HIV-1 BaL Infection. Maia, C.M.A., S. Pasetto, E.S.J.P. Raimundo, J.F. Tavares, E. Costa, and R.M. Murata. Natural Product Research, 2021: p. 1-5. PMID[33729064].
[PubMed]. HIV_04_2021.
8. Broadly Active Zinc Finger Protein-guided Transcriptional Activation of HIV-1. Scott, T.A., D. O'Meally, N.A. Grepo, C. Soemardy, D.C. Lazar, Y. Zheng, M.S. Weinberg, V. Planelles, and K.V. Morris. Molecular Therapy- Methods & Clinical Delivery, 2021. 20: p. 18-29. PMID[33335944]. PMCID[PMC7726486].
[PubMed]. HIV_04_2021.
9. Identification of Aristolactam Derivatives That Act as Inhibitors of Human Immunodeficiency Virus Type 1 Infection and Replication by Targeting Tat-mediated Viral Transcription. Shin, Y., C.M. Park, H.G. Kim, D.E. Kim, M.S. Choi, J.A. Kim, B.S. Choi, and C.H. Yoon. Virologica Sinica, 2021. 36(2): p. 254-263. PMID[32779073]. PMCID[PMC8087725].
[PubMed]. HIV_04_2021.
10. Anti-HIV and Antibacterial Activities of Novel 2-(3-Substituted-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-diones. Sulthana, M.T., K. Chitra, V. Alagarsamy, G. Saravanan, and V.R. Solomon. Russian Journal of Bioorganic Chemistry, 2021. 47(1): p. 112-121. ISI[000630869600007].
[WOS]. HIV_04_2021.
11. An Original Pronucleotide Strategy for the Simultaneous Delivery of Two Bioactive Drugs. Villard, A.L., A.M. Aubertin, S. Peyrottes, and C. Périgaud. European Journal of Medicinal Chemistry, 2021. 216: 113315. PMID[33711763].
[PubMed]. HIV_04_2021.
12. Fejerlectin, a Lectin-like Peptide from the Skin of Fejervarya limnocharis, Inhibits HIV-1 Entry by Targeting gp41. Xiong, W., C. Zhou, S. Yin, J. Chai, B. Zeng, J. Wu, Y. Li, L. Li, and X. Xu. ACS Omega, 2021. 6(9): p. 6414-6423. PMID[33718732]. PMCID[PMC7948434].
[PubMed]. HIV_04_2021.
13. Chemical Constituents of Cassia abbreviata and Their Anti-HIV-1 Activity. Yang, X., Z. He, Y. Zheng, N. Wang, M. Mulinge, J.C. Schmit, A. Steinmetz, and C. Seguin-Devaux. Molecules, 2021. 26(9): 2455. PMID[33922460].
[PubMed]. HIV_04_2021.
14. Design, Synthesis, and Structure Activity Relationship Analysis of New Betulinic acid Derivatives as Potent HIV Inhibitors. Zhao, Y., C.H. Chen, S.L. Morris-Natschke, and K.H. Lee. European Journal of Medicinal Chemistry, 2021. 215: 113287. PMID[33639343].
[PubMed]. HIV_04_2021.
15. A Targeted Covalent Small Molecule Inhibitor of HIV-1 Fusion. Zhou, G.Y., L. He, K.H. Li, C.C.S. Pedroso, and M. Gochin. Chemical Communications, 2021. 57(37): p. 4528-4531. PMID[33956029].
[PubMed]. HIV_04_2021.
Patent Citations
16. Preparation of N-Substituted-4-oxo-3,4-dihydropyrido[2,3-D]pyrimidin-2-yl Carboxamide Derivatives as Inhibitors of the Human Immunodeficiency Virus Replication. Bowsher, M.S., E.P. Gillis, C. Iwuagwu, B.N. Naidu, K.E. Parcella, and M. Patel. Patent. 2021. 2020-IB59103 2021064571: 165pp.
[Patent]. HIV_04_2021.
17. Indaozlyldihydroquinazolinones as Inhibitors of Human Immunodeficiency Virus Replication and Their Preparation. Bowsher, M.S., K.E. Parcella, C. Iwuagwu, and E.P. Gillis. Patent. 2021. 2020-IB59377 2021070054: 114pp.
[Patent]. HIV_04_2021.
18. Preparation of 3,4-Dihydroquinazolin-2-ylacetamides as Human Immunodeficiency Virus Replication Inhibitors. Bowsher, M.S., K.E. Parcella, M. Patel, E.P. Gillis, and B.N. Naidu. Patent. 2021. 2020-IB59274 2021064677: 138pp.
[Patent]. HIV_04_2021.
19. Preparation of N-[1-[(Indazol-7-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]-2-phenylethyl]carboxamide Derivatives as Inhibitors of the Human Immunodeficiency Virus Replication. Naidu, B.N. and M. Patel. Patent. 2021. 2020-IB59101 2021064570: 141pp.
[Patent]. HIV_04_2021.